Business Wire - November 15, 2005
Dr. Min Lu, Associate Professor of Biochemistry at Weill Medical College of Cornell University in New York City, identified this novel and proprietary domain of gp41, and the 3-dimensional protein structure information forms the basis of the license. Dr. Lu is a recognized leader in the area of gp41 biology and the mechanism of HIV infection, and has been a key collaborator with Locus on this program. This is the second structure Locus has licensed from Dr. Lu's laboratory.
Most currently approved therapies for HIV infection involve approaches to suppress viral replication once the virus has entered the host cell. In contrast, gp41 inhibitors prevent HIV from ever getting into the cell, which may allow preventative therapy.
"HIV fusion and viral infection are dependent upon gp41. Therefore, blocking this protein's function with an oral drug would represent an important new treatment for suppressing and preventing HIV-1 infection," said William R. Moore, Jr., Ph.D., Vice President of Research and Development and Chief Science Officer at Locus.
"I am excited to be continuing my relationship with Locus. They bring unique computational capabilities to our collaboration, particularly with regard to binding site identification, drug design, and protein motion simulation," commented Dr. Lu.
Starting with a protein crystal structure, its in silico library of 40,000 molecular fragments, and one of the world's largest Linux-based supercomputer clusters, Locus computationally maps relevant ligand binding sites on protein targets, constructs antagonists to those sites, while simultaneously optimizing the drug candidate's ADMET properties. Locus creates and evaluates custom-built, project specific 'virtual libraries' of candidate ligands that surpass 1 billion potential compounds, exceeding the size of any physical screening library by orders of magnitude.
Locus can model physically realistic long-range timescales of protein motion (10 times longer than other approaches) and compute binding potencies in almost real time. Other computational methods with similar accuracy are 10,000 times slower. Locus typically needs to synthesize only hundreds of compounds from its virtual libraries to generate highly potent, orally-active lead molecules.
About Locus Pharmaceuticals
Locus Pharmaceuticals, Inc. is a world leader in computational drug design. Since 2000, Locus has developed unique and potentially transformational capabilities for the in silico design and optimization of small molecule drugs. These proprietary computational approaches are combined with in-house expertise in chemistry, biology and crystallography to create a fully integrated drug discovery platform. Locus believes that its capabilities offer the potential to substantially lower the cost of drug discovery and greatly increase the speed of advancing novel therapies to clinical trials and, ultimately, to the market.
Locus is developing oral drug therapies to address major unmet medical needs, principally in cancer and inflammation. All of the Company's development programs emanate from its computational technology. LP-261, Locus' lead oncology compound, is an orally-administered therapeutic that blocks tumor growth potentially through both anti-mitotic and anti-angiogenic mechanisms of action. It has also been shown to be active against resistant cell lines. Locus expects to file an IND for this compound around the end of this year.
In Locus' lead inflammation program, Locus has created uniquely selective, highly potent, and orally-active p38 inhibitors that target an allosteric binding site rather than the ATP site, which other drug developers are pursuing. Allosteric sites may offer an improved safety profile over ATP site inhibitors as well as provide a dual mode of action.
In addition to the AIDS/HIV program, other earlier stage projects include a program to develop multi-kinase inhibitors that block several key growth stimulation pathways simultaneously, and Heat Shock Protein 90 which is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
Locus is privately-held and has approximately 40 employees.
***
Contacts: Locus Pharmaceuticals, Inc., Robert Dickey IV, 215-358-2006
051115
BW051107
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .